How many prescriptions did Lilly's Foundayo receive in its first full week on the U.S. market, and when was it approved and launched?

Lilly's obesity pill Foundayo received 1,390 prescriptions in the U.S. as of the week ended April 10, according to IQVIA data cited by an analyst. The drug was approved on April 1, prescriptions were accepted immediately on LillyDirect, shipping began on April 6, and broad availability through U.S. retail pharmacies and telehealth providers started on April 9.

How does Foundayo's first-week prescription volume compare to Novo Nordisk's oral Wegovy at launch and in the same week?

Novo Nordisk's oral Wegovy achieved 3,071 U.S. prescriptions in just the first four days after its January 5 launch, vastly outpacing Foundayo’s 1,390 prescriptions in its first full week ending April 10; in that same week (ended April 10), oral Wegovy had 113,354 prescriptions—up from 105,366 the prior week—while Foundayo had only 1,390, highlighting a stark early disparity in uptake.

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

Apr 17, 2026

Eli Lilly's obesity pill Foundayo recorded 1,390 U.S. prescriptions in its debut week, trailing Novo Nordisk's oral Wegovy. Launch data underscores intensifying competition in the oral obesity drug market, lifting Lilly shares nearly 3%.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks